文献速递乳腺外科

EORTC QLQ-BRECON23 乳房重建生活质量问卷的国际验证

International validation of the European Organisation for Research and Treatment of Cancer QLQ-BRECON23 quality-of-life questionnaire for women undergoing breast reconstruction.
PubMed 文献 · Br J Surg · 2017-11-08

该研究对 EORTC BRECON 模块进行国际多中心验证,纳入 438 例接受乳房切除和重建的乳腺癌患者,最终形成 QLQ-BRECON23 问卷。结果显示该问卷具有良好的信度、效度、反应度和可接受性,可用于评估乳房重建后的生活质量和满意度。

要点

  • QLQ-BRECON23 是国际验证的乳房重建生活质量评估工具。
  • 应联合 EORTC QLQ-C30 和 QLQ-BR23 一起使用。
  • 问卷可区分重建类型、时机、放疗和并发症等临床分组。

核心结论

  • QLQ-BRECON23 是经过国际验证的工具,用于评估乳房重建后的生活质量和满意度。

研究设计与样本

  • 遵循 EORTC 模块开发指南,从 7 个国家 28 个中心招募 438 例乳腺癌患者,包括前瞻性队列 234 例和横断面队列 204 例。

主要发现

  • QLQ-BRECON24 量表和条目能区分不同临床特征组(如重建类型和时机、放疗、手术并发症),效应量中等。

临床怎么用

  • 临床中可将 QLQ-BRECON23 与 EORTC QLQ-C30 和 QLQ-BR23 联合使用,评估乳房重建患者的生活质量和满意度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim was to carry out phase 4 international field-testing of the European Organisation for Research and Treatment of Cancer (EORTC) breast reconstruction (BRECON) module. The primary objective was finalization of its scale structure. Secondary objectives were evaluation of its reliability, validity, responsiveness, acceptability and interpretability in patients with breast cancer undergoing mastectomy and reconstruction. METHODS: The EORTC module development guidelines were followed. Patients were recruited from 28 centres in seven countries. A prospective cohort completed the QLQ-BRECON15 before mastectomy and the QLQ-BRECON24 at 4-8 months after reconstruction. The cross-sectional cohort completed the QLQ-BRECON24 at 1-5 years after reconstruction, and repeated this 2-8 weeks later (test-retest reliability). All participants completed debriefing questionnaires. RESULTS: A total of 438 patients were recruited, 234 in the prospective cohort and 204 in the cross-sectional cohort. A total of 414 reconstructions were immediate, with a comparable number of implants (176) and donor-site flaps (166). Control groups comprised patients who underwent two-stage implant procedures (72, 75 per cent) or delayed reconstruction (24, 25 per cent). Psychometric scale validity was supported by moderate to high item-own scale and item-total correlations (over 0·5). Questionnaire validity was confirmed by good scale-to-sample targeting, and computable scale scores exceeding 50 per cent, except nipple cosmesis (over 40 per cent). In known-group comparisons, QLQ-BRECON24 scales and items differentiated between patient groups defined by clinical criteria, such as type and timing of reconstruction, postmastectomy radiotherapy and surgical complications, with moderate effect sizes. Prospectively, sexuality and surgical side-effects scales showed significant responsiveness over time (P < 0·001). Scale reliability was supported by high Cronbach's α coefficients (over 0·7) and test-retest (intraclass correlation more than 0·8). One item (finding a well fitting bra) was excluded based on high floor/ceiling effects, poor test-retest and weak correlations in factor analysis (below 0·3), thus generating the QLQ-BRECON23 questionnaire. CONCLUSION: The QLQ-BRECON23 is an internationally validated tool to be used alongside the EORTC QLQ-C30 (cancer) and QLQ-BR23 (breast cancer) questionnaires for evaluating quality of life and satisfaction after breast reconstruction.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Winters ZE, Afzal M, Rutherford C, et al. International validation of the European Organisation for Research and Treatment of Cancer QLQ-BRECON23 quality-of-life questionnaire for women undergoing breast reconstruction. Br J Surg. 2017. PMID: 29116657. doi:10.1002/bjs.10656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。